Ventana Biotech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNTA research report →
Companywww.launchpadcafe.net
Ventana Biotech, Inc. , a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses.
- CEO
- Janne Christensen
- IPO
- 2009
- HQ
- Denver, CH
Price Chart
Valuation
- Market Cap
- $101.87K
- P/E
- 23.10
- P/S
- 0.89
- P/B
- -36.90
- EV/EBITDA
- 1.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 87.99%
- Net Margin
- 75.18%
- ROE
- -162.12%
- ROIC
- 145.45%
Growth & Income
- Revenue
- $114.58K · 177.01%
- Net Income
- $86.14K · 333.08%
- EPS
- $0.00 · 300.00%
- Op Income
- $100.81K
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.08
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- -3.53
- Avg Volume
- 486
Get TickerSpark's AI analysis on VNTA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VNTA Coverage
We haven't published any research on VNTA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VNTA Report →